APA (7th ed.) Citation

RV, O., O, B., N, R., T, S., A, S., S, W., & D, R. (2026). Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach. Diabetes, obesity & metabolism, 28(7), 5982. https://doi.org/10.1111/dom.70769

Chicago Style (17th ed.) Citation

RV, Overgaard, Birkhan O, Rathor N, Sparsø T, Strathe A, Wharton S, and Rubino D. "Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach." Diabetes, Obesity & Metabolism 28, no. 7 (2026): 5982. https://doi.org/10.1111/dom.70769.

MLA (9th ed.) Citation

RV, Overgaard, et al. "Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach." Diabetes, Obesity & Metabolism, vol. 28, no. 7, 2026, p. 5982, https://doi.org/10.1111/dom.70769.